CMV(poly)-CTL therapy (Atara)

N/A

Report date: 2025/01/15 13:54:19

Base Information

Drug NameCMV(poly)-CTL therapy (Atara)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocytes modulators
TargetsUpdating
Therapy Area/IndicationsMultiple SclerosisStomach NeoplasmsNasopharyngeal Carcinoma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia and New Zealand
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesQueensland Institute Of Medical Research
China Registration ClassN/A

Develop Information

Active CompaniesQueensland Institute Of Medical ResearchAtara Biotherapeutics Inc
Inactive CompaniesN/A
Active IndicationsMultiple SclerosisStomach NeoplasmsNasopharyngeal Carcinoma +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A